EICHOR
● Active Not Recruiting
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
Condition: Breast Carcinoma In Situ · Invasive Breast Carcinoma · Stage I Breast Cancer AJCC v7 · Sponsor: National Cancer Institute (NCI)
About this study
This randomized phase III trial studies how well pembrolizumab works in treating patients with triple-negative breast cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (919)
| University of Alabama at Birmingham Cancer Center | Birmingham, Alabama, United States | — |
| Southern Cancer Center PC-Daphne | Daphne, Alabama, United States | — |
| Southern Cancer Center PC-Mobile | Mobile, Alabama, United States | — |
| Southern Cancer Center PC-Providence | Mobile, Alabama, United States | — |
| Southern Cancer Center PC-Springhill | Mobile, Alabama, United States | — |
| University of South Alabama Mitchell Cancer Institute | Mobile, Alabama, United States | — |
| Alaska Oncology and Hematology LLC | Anchorage, Alaska, United States | — |
| Anchorage Oncology Centre | Anchorage, Alaska, United States | — |
| Katmai Oncology Group | Anchorage, Alaska, United States | — |
| Providence Alaska Medical Center | Anchorage, Alaska, United States | — |
| Fairbanks Memorial Hospital | Fairbanks, Alaska, United States | — |
| Banner MD Anderson Cancer Center | Gilbert, Arizona, United States | — |
+ 907 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02954874